TORONTO, July 02, 2025 (GLOBE NEWSWIRE) -- Dayforce, Inc. (NYSE : DAY; TSX : DAY), un chef de file mondial en gestion du capital humain qui améliore la vie au travail, a annoncé aujourd'hui le repositionnement de marque de sa solution de gestion de la paie et de gestion des RH pour les PME sous le nom de Powerpay par Dayforce, ce qui signifie que l'entreprise met l'accent sur une nouvelle approche stratégique et s'engage de manière continue à répondre aux besoins uniques et en constante évolution de plus de ...

TORONTO, July 02, 2025 (GLOBE NEWSWIRE) -- Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management (HCM) leader that makes work life better, today announced the rebranding of its payroll and HR solution for Canadian small and mid-sized businesses (SMBs) as Powerpay by Dayforce, signaling a renewed strategic focus and ongoing commitment to meeting the unique and evolving needs of its more than 46,000 customers across Canada. SMBs drive Canada's economy, contributing billions to its GDP each y ...

Company Appoints Elevate IR as Investor Relations Firm of Record MINNEAPOLIS, MN, July 01, 2025 (GLOBE NEWSWIRE) -- SharpLink Gaming, Inc. (Nasdaq: SBET) ("SharpLink" or the "Company"), the largest publicly traded holder of Ethereum ("ETH") in the world, today announced that the Company has strategically increased its total holdings of ETH to 198,167, acquiring an additional 9,468 ETH for $22,825,734 (inclusive of fees and expenses) at an weighted average price of $2,411 per ETH (inclusive of fees and expen ...

ROSELAND, N.J., June 25, 2025 /PRNewswire/ -- ADP (Nasdaq: ADP), a leading global provider of Human Capital Management (HCM) solutions, is scheduled to release its financial results for the fourth fiscal quarter ending June 30, 2025 before the opening of the Nasdaq on Wednesday, July 30, 2025. ADP will also be hosting a conference call at 8:30 a.m. ET on July 30, 2025 to discuss these results. Maria Black, President & Chief Executive Officer, Peter Hadley, Chief Financial Officer and Matthew Keating, Vice P ...

MONTREAL, June 18, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. ("Cannara", "the Company", "us" or "we") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium- grade cannabis products at disruptive prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., is proud to announce that in recognition of its continued commitment to product excellence and innovation, Cannara was honored with two awards at the 6th Annual Grow Up Awards Gala held in Toronto on M ...

Fortifies Balance Sheet and Reinforces Disciplined Capital Management ApproachCHASKA, Minn., June 12, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has received the remaining $10 million in proceeds from the previously disclosed sale of its excess high-speed, multi-purpose 10-head isolator filler. The buyer elected to complete the full payment ahead of schedule, opting t ...

Huntington Bancshares (HBAN) 2025 Conference June 11, 2025 08:15 AM ET Speaker0 Up next, we have Huntington Bank. I'll get our disclosures out of the way For important disclosures, please see the Morgan Stanley research disclosure website, morganstanley.com/researchdisclosures. The taking of photographs and use of recording devices is not allowed. If you have any questions, please reach out to your Morgan Stanley sales representative. And with that out of the way, we're delighted to have with us today Hunti ...

Financial Data and Key Metrics Changes - The company generated net sales of $116 million in Q1 2025, a decrease of 14% compared to $135 million in Q1 2024 [6][16] - Adjusted EBITDA for Q1 2025 was $3 million, down from $15.5 million in the same period last year [6][16] - Operating expenses decreased by $5 million year-over-year [5][10] - Gross profit margin declined to 26% in Q1 2025 from 31% in the previous year [18] Business Line Data and Key Metrics Changes - Metem sales increased by 14% year-over-year, while Diamond sales rose by 17% due to increased peanut acreage [8][9] - The absence of a previously canceled herbicide product negatively impacted sales [16] - The company faced challenges in the Mexican agave market and drought conditions in Australia, affecting overall performance [8][16] Market Data and Key Metrics Changes - Inventory levels at distributors are down nearly 23% compared to the previous year, indicating a prolonged destocking period [24] - Corn plantings are at historically high levels, which may positively impact demand for the company's products [24] - The company noted a competitive pricing environment, particularly in the fungicide and herbicide categories [56][58] Company Strategy and Development Direction - The company is focused on cost containment and improving net working capital, with a goal of achieving a 15% adjusted EBITDA margin over the long term [10][48] - A transformation plan is in place to streamline operations and improve financial results [26] - The company is exploring options for a longer-term capital structure to replace its current credit agreement [21] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about a recovery in demand as inventory levels are at historic lows [23][62] - The company has adjusted its full-year adjusted EBITDA target range to $40 million to $44 million, down from $45 million to $52 million [12] - Management highlighted the importance of executing the transformation plan to position the company for a cyclical upturn [22][26] Other Important Information - The company faced delays in filing its 10-K and 10-Q due to internal control matters and the need for a detailed review of major assets [13][15] - The company is working on a remediation plan to address identified material weaknesses in internal controls [15] Q&A Session Summary Question: Can you elaborate on the year-over-year top line performance? - Management noted that the removal of the Dactyl product significantly impacted top line sales, along with challenges in the agave market and drought in Australia [31][32] Question: What are the expectations for cash taxes this year? - The company expects cash taxes to be in the range of $4 million to $5 million due to international obligations [43] Question: Can you provide details on pricing pressures and competitive environment? - Management indicated that competitive pricing was influenced by inventory levels and not necessarily by specific product competition, with expectations for improvement in the future [56][58]

Core Insights - Incannex Healthcare Inc. (NASDAQ: IXHL) reported a reduction in R&D expenses to $2.74 million in Q3 2025 from $3.28 million in the same quarter of the previous year, indicating effective cost containment measures [1] - SG&A expenses decreased significantly to $2.27 million from $4.14 million year-over-year, driven by strategic cost-saving initiatives [1] - The net loss for the quarter was reduced to $3.97 million from $6.03 million year-over-year, supported by improved operational efficiencies [1] - Cash and cash equivalents increased to $6.7 million from $2.1 million at the end of Q2 2024, attributed to recent financing activities and R&D tax incentive payments [1] Financial Management - IXHL plans to issue approximately $24.7 million worth of shares to repurchase all outstanding Series A Warrants, representing 347.2 million shares that could be dilutive, showcasing management's proactive approach to capital management [7] - The company secured $12.5 million in private placement funding, priced at-the-market [7] - A probability adjusted DCF model estimates a share valuation range of $5.30 to $5.94, with a midpoint of $5.61 [7]

Core Insights - Incannex Healthcare Inc. successfully completed a capital raise of $16.7 million through its at-the-market facility, with $12.5 million allocated to cancel up to 50.4% of Series A Warrants previously issued [1][2][3] - The cancellation of these warrants significantly reduces potential future dilution, as up to 5,841,038 warrants are eligible for cancellation, which could have led to the issuance of up to 175.2 million additional shares [2][3] - The initiative reflects the company's commitment to responsible capital management and enhancing shareholder value ahead of the Phase 2 results for its lead product, IHL-42X [3] Company Overview - Incannex is a clinical-stage biopharmaceutical company focused on developing combination drug therapies targeting chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder [7] - The lead product, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide, currently in the RePOSA Phase 2/3 clinical trial, which aims to enroll over 560 patients globally [5][6] - IHL-42X has shown promising results in prior trials, reducing the Apnea-Hypopnea Index by an average of 51% at the lowest dosage [6]